HomeNewsWegovy-maker Novo Nordisk raises outlook as gross sales of its weight-loss drug...

Wegovy-maker Novo Nordisk raises outlook as gross sales of its weight-loss drug soar Get hold of US

A collection of injector pens for the Saxenda weight reduction drug are proven on this picture illustration in Chicago, Illinois, U.S., March 31, 2023. 

Jim Vondruska | Reuters

Novo Nordisk, which makes the weight-loss drug Wegovy, raised its outlook for 2023 Thursday, because it reported hovering gross sales.

The Danish pharmaceutical firm reported a 30% enhance in gross sales (at fixed alternate charges) for the primary half of this 12 months, whereas working revenue additionally rose 32%.

Its diabetes and weight problems division carried out significantly effectively, bolstered by curiosity in its blockbuster injection Wegovy.

“The [sales] development is pushed by growing demand for our GLP-1-based diabetes and weight problems remedies, and we’re serving extra sufferers than ever earlier than,” Lars Fruergaard Jørgensen, president and CEO, stated in a press release. “The efficiency within the first six months has enabled us to lift the outlook for the complete 12 months.”

Final week, late-stage trial knowledge confirmed that Wegovy decreased the danger of main cardiovascular occasions reminiscent of coronary heart assaults or strokes by 20%, in contrast with a placebo, sending shares increased.

The outcomes of the intently watched “SELECT” trial, which exceeded expectations, have been seen as a significant enhance for the corporate’s hopes of shifting past Wegovy’s picture as a “self-importance drug.”

Shares are up nearly 1% in pre-market buying and selling.

This can be a creating story and shall be up to date shortly.

Sam Meredith contributed to this report.

#Wegovymaker #Novo #Nordisk #raises #outlook #gross sales #weightloss #drug #soar

Continue to the category


Please enter your comment!
Please enter your name here

- Advertisment -spot_img

Most Popular

Recent Comments